NYSE:VOR Vor Biopharma (VOR) Stock Price, News & Analysis $0.91 +0.08 (+9.66%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.87▼$1.1650-Day Range$0.80▼$1.0152-Week Range$0.70▼$3.14Volume21.34 million shsAverage Volume460,774 shsMarket Capitalization$61.98 millionP/E RatioN/ADividend YieldN/APrice Target$10.92 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Get Vor Biopharma alerts: Email Address Vor Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,102.3% Upside$10.92 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.35Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.51) to ($1.18) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.15 out of 5 starsMedical Sector678th out of 910 stocks 3.5 Analyst's Opinion Consensus RatingVor Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVor Biopharma has only been the subject of 3 research reports in the past 90 days.Read more about Vor Biopharma's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for VOR. Previous Next 0.0 Dividend Strength Dividend YieldVor Biopharma does not currently pay a dividend.Dividend GrowthVor Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VOR. Previous Next 3.0 News and Social Media Coverage News SentimentVor Biopharma has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Vor Biopharma this week, compared to 1 article on an average week.Search Interest8 people have searched for VOR on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.MarketBeat Follows3 people have added Vor Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vor Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.70% of the stock of Vor Biopharma is held by insiders.Percentage Held by Institutions97.29% of the stock of Vor Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vor Biopharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vor Biopharma are expected to grow in the coming year, from ($1.51) to ($1.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vor Biopharma is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vor Biopharma is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Vor Biopharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWhy billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. Click here for my exclusive video About Vor Biopharma Stock (NYSE:VOR)Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More VOR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VOR Stock News HeadlinesSeptember 6 at 6:38 PM | markets.businessinsider.comVor Biopharma (VOR) Receives a Buy from BarclaysSeptember 6 at 6:38 PM | markets.businessinsider.comVor Biopharma’s Promising Clinical Trials and Strategic Developments Merit a Buy RatingSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. September 6 at 6:38 PM | msn.comWhat's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?September 6 at 5:54 AM | markets.businessinsider.comNew Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted TherapiesSeptember 6 at 5:54 AM | markets.businessinsider.comPromising Clinical Outcomes and Strategic Acquisitions Bolster Buy Rating for Vor BiopharmaSeptember 5 at 4:01 PM | globenewswire.comNew Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted TherapiesSeptember 5 at 9:49 AM | finance.yahoo.comHere's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash WiselySeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 28, 2024 | globenewswire.comVor Bio to Participate in Upcoming Investor ConferencesAugust 13, 2024 | markets.businessinsider.comBuy Rating Backed by Clinical and Financial Strengths at Vor BiopharmaAugust 9, 2024 | markets.businessinsider.comOptimistic Outlook on Vor Biopharma’s Pipeline and Financial Stability Drives Buy RatingAugust 9, 2024 | markets.businessinsider.comWedbush Keeps Their Buy Rating on Vor Biopharma (VOR)August 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vor Biopharma Amid Anticipated Clinical Trials and Strong Financial FootingAugust 9, 2024 | investorplace.comVOR Stock Earnings: Vor Biopharma Beats EPS for Q2 2024August 8, 2024 | globenewswire.comVor Bio Reports Second Quarter 2024 Financial Results and Provides Company UpdateAugust 2, 2024 | globenewswire.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 9, 2024 | globenewswire.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive VOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vor Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry N/A Sub-IndustryPharmaceutical Products Current SymbolNYSE:VOR CUSIPN/A CIK1817229 Webwww.vorbiopharma.com Phone617-655-6580FaxN/AEmployees140Year FoundedN/APrice Target and Rating Average Stock Price Target$10.92 High Stock Price Target$17.50 Low Stock Price Target$3.00 Potential Upside/Downside+1,102.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares68,260,000Free Float65,052,000Market Cap$61.98 million OptionableNot Optionable Beta-0.34 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Robert Ang M.B.A. (Age 49)M.D., MBBS, President, CEO & Director Comp: $943.91kDr. Tirtha Chakraborty Ph.D. (Age 51)Chief Scientific Officer Comp: $661.98kDr. Eyal C. Attar M.D. (Age 53)Chief Medical Officer Comp: $660.55kDr. Siddhartha Mukherjee DPHIL (Age 53)M.D., Ph.D., Scientific Founder & Chairman of Scientific Advisory Board Dr. Nathan D. Jorgensen M.B.A. (Age 47)Ph.D., Chief Financial Officer Comp: $608.48kMs. Tania Philipp (Age 52)Chief People Officer Mr. John C. King M.B.A. (Age 48)Chief Commercial Officer Mr. Samir Vattompadam M.S.Senior Vice President of Portfolio Strategy & Program ManagementMr. David Phillips M.B.A.Senior VP & Head of QualityMore ExecutivesKey CompetitorsESSA PharmaNASDAQ:EPIXAmarinNASDAQ:AMRNSOPHiA GENETICSNASDAQ:SOPHEnanta PharmaceuticalsNASDAQ:ENTAAlpha TeknovaNASDAQ:TKNOView All CompetitorsInsiders & InstitutionsPoint72 Asia Singapore Pte. Ltd.Bought 63,262 shares on 8/15/2024Ownership: 0.093%Cubist Systematic Strategies LLCBought 52,914 shares on 8/14/2024Ownership: 0.078%Hsbc Holdings PLCBought 31,333 shares on 8/12/2024Ownership: 0.072%Renaissance Technologies LLCBought 160,642 shares on 8/9/2024Ownership: 0.726%Acadian Asset Management LLCBought 27,597 shares on 8/6/2024Ownership: 0.119%View All Insider TransactionsView All Institutional Transactions VOR Stock Analysis - Frequently Asked Questions How have VOR shares performed this year? Vor Biopharma's stock was trading at $2.25 at the start of the year. Since then, VOR stock has decreased by 59.6% and is now trading at $0.9080. View the best growth stocks for 2024 here. How were Vor Biopharma's earnings last quarter? Vor Biopharma Inc. (NYSE:VOR) issued its quarterly earnings data on Thursday, August, 8th. The company reported ($0.41) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.41). When did Vor Biopharma IPO? Vor Biopharma (VOR) raised $150 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Evercore ISI, Barclays and Stifel served as the underwriters for the IPO. Who are Vor Biopharma's major shareholders? Vor Biopharma's top institutional investors include Renaissance Technologies LLC (0.73%), Acadian Asset Management LLC (0.12%), Point72 Asia Singapore Pte. Ltd. (0.09%) and Cubist Systematic Strategies LLC (0.08%). View institutional ownership trends. How do I buy shares of Vor Biopharma? Shares of VOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:VOR) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vor Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vor Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VOR Stock Alerts